Educational content only. Not medical advice. Consult a qualified physician.
Thymosin Beta-4 peptide
RecoveryResearch-only. Not FDA-approved for any indication. Banned by WADA in competitive sports.

TB-500

Thymosin Beta-4

TB-500 is a synthetic version of Thymosin Beta-4, a naturally occurring peptide present in nearly all human and animal cells. It plays a role in cell migration, proliferation, and differentiation. Research has focused on its potential to promote tissue repair and reduce inflammation.
Reported Benefits

Potential Benefits

  • May promote wound healing and tissue repair based on preclinical research
  • Studies suggest anti-inflammatory effects
  • Research indicates potential to support cardiac tissue repair after injury
  • May enhance flexibility and reduce scar tissue formation
  • Preclinical data suggests promotion of new blood vessel growth
Research Dosing

Recommended Starting Dose

2-2.5 mg subcutaneously, twice per week

Based on published research protocols. Not a prescription.

Dosing Protocol

A common loading protocol involves 2-2.5 mg injected subcutaneously twice weekly for 4-6 weeks, followed by a maintenance phase of once weekly or biweekly. Often cycled with BPC-157 for recovery applications.

DOSING INFORMATION DISCLAIMER: Any dosing information, protocols, or ranges discussed on this site are drawn from published research studies and clinical literature. They are presented for educational reference only and must not be used as self-medication guidance.

Research Timeline

Expected Timeline

Phase 1

Users anecdotally report initial improvements in 2-3 weeks, with more substantial recovery benefits emerging over 4-8 weeks.

Regulatory

Research Status

Research-only. Not FDA-approved for any indication. Banned by WADA in competitive sports.

The regulatory status of peptides can change at any time. Verify current FDA classification and legal status in your jurisdiction before seeking medical consultation about this compound.

Safety Profile

Potential Side Effects

  • Limited human clinical data
  • Headache reported anecdotally
  • Possible nausea
  • Injection site irritation
  • Theoretical concern about promoting growth in existing tumors (not confirmed)
  • Fatigue in some anecdotal reports
Related Research

More in Recovery

Medical Disclaimer

EDUCATIONAL CONTENT ONLY: The peptide information presented on this page is compiled from published scientific literature, peer-reviewed research, and publicly available clinical data. It is provided strictly for educational purposes and does not constitute medical advice, an endorsement of any specific peptide, or a recommendation for treatment. Many peptides discussed on this site have not received FDA approval for human therapeutic use. Some may be under active regulatory review or subject to restrictions on compounding under FDA Section 503A and 503B frameworks. The regulatory status of individual peptides can change at any time. Readers should verify the current legal status of any peptide in their jurisdiction before pursuing further information or consultation. If you are considering peptide therapy, seek guidance from a licensed physician or healthcare provider who specializes in peptide-based treatments and operates within applicable federal and state regulations.